QUIDEL CORP (US2197981051) QuidelOrtho to Host Investor Day on December 13, 2022
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Announces Separation of Chairman and...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho” or the “Company”), a global provider of innovative in vitro diagnostic (IVD) technologies designed for point-of-care...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho and Runda Medical Form Joint Venture...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho” or the “Company”), a global provider of innovative in vitro diagnostics (IVD) technologies designed for point-of-care...
View ArticleQUIDEL CORP (US2197981051) Health Canada Grants License for Quidel®...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho to Present at the J.P. Morgan...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Reports Preliminary Revenue Results...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Reports Fourth Quarter and Full Year...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho to Participate in the Raymond James...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Receives De Novo FDA Authorization for...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Announces the Formation of the...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Reports Preliminary Revenue Results...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Reports First Quarter 2023 Financial...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho to Participate in William Blair 43rd...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho to Report Second Quarter 2023...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Partners With BYG4lab® to Strengthen...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Ranks No. 1 in Customer Satisfaction...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Reports Second Quarter 2023 Financial...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho to Participate in the Morgan Stanley...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs...
View ArticleQUIDEL CORP (US2197981051) QuidelOrtho Reports Preliminary Revenue Results...
SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care...
View Article
